Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | GDC-0919 |
Trade Name | |
Synonyms | Navoximod|NLG919|RG6078 |
Drug Descriptions |
GDC-0919 (Navoximod) inhibits indoleamine 2,3-dioxygenase 1 (IDO1) to prevent tryptophan breakdown in the tumor microenvironment, thereby activating a cytotoxic immune response against IDO1 expressing tumor cells (PMID: 25054064, PMID: 31124055). |
DrugClasses | IDO1 Inhibitor 12 Immune Checkpoint Inhibitor 155 |
CAS Registry Number | 1402837-78-8 |
NCIT ID | C113793 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + GDC-0919 | Atezolizumab GDC-0919 | 0 | 0 |
GDC-0919 | GDC-0919 | 0 | 2 |
GDC-0919 + NLG802 | GDC-0919 NLG802 | 0 | 1 |